Total Intravenous Anaesthesia (TIVA) Versus Spinal Anaesthesia in Patients Undergoing Transurethral Prostate Resection
TURPS
TIVA Versus Spinal Anaesthesia in Patients Undergoing Transurethral Prostate Resection
1 other identifier
interventional
101
1 country
1
Brief Summary
Comparison of total intravenous anaesthesia with spinal anaesthesia in patients undergoing transurethral prostate resection
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Jan 2006
Typical duration for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2009
CompletedFirst Submitted
Initial submission to the registry
April 7, 2010
CompletedFirst Posted
Study publicly available on registry
May 6, 2010
CompletedMay 6, 2010
May 1, 2010
3.3 years
April 7, 2010
May 5, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
patient satisfaction
Patient satisfaction was measured asking the patient about satisfaction with anaesthesia using a 5-point Linkert scale: totally satisfied - satisfied - neither satisfied nor dissatisfied - dissatisfied - totally dissatisfied Time frame: Start anaesthesia to end post anaesthestic care unit
4 hours
Secondary Outcomes (1)
time in PACU
4 hours
Study Arms (2)
TIVA
ACTIVE COMPARATORTotal intravenous anaesthesia (TIVA) with propofol and remifentanil
Spinal
ACTIVE COMPARATORSpinal anaesthesia with bupivacaine and fentanyl
Interventions
Eligibility Criteria
You may qualify if:
- years and older
- signed informed consent
- elective transurethral prostata resection
You may not qualify if:
- ASA more than 3
- kidney disease, liver disease
- intolerance against bupivacaine, fentanyl, propofol og remifentanil
- chronic pulmonary disease
- dementia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Asker & Baerum Hospital
Rud, 1309, Norway
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Vegard Dahl, MD, PhD
Asker & Baerum Hospital
- PRINCIPAL INVESTIGATOR
Elisabet Andersson
Asker & Baerum Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
April 7, 2010
First Posted
May 6, 2010
Study Start
January 1, 2006
Primary Completion
May 1, 2009
Study Completion
May 1, 2009
Last Updated
May 6, 2010
Record last verified: 2010-05